

Planned filings 2014 to ≥ 2018

2014	2015	2016	2017	≥ 2018
LBH589* Multiple Myeloma	BKM120 mBC ER+ AI resistant/mTOR naive	BYM338 sIBM ⁹	DEB025 HCV infection	AUY922 Solid tumors
LCQ908 FCS ¹	PKC412 AML ⁵	CTL019 Acute Lymphoblastic Leukemia	KAE609 Malaria	BAF312 Multiple sclerosis
LCZ696 Heart failure (REF) ²	Afinitor® Non-functioning GI and Lung NET ⁶	Fovista® Wet AMD	LCI699 Cushing's Disease	BCT197 COPD ¹⁸
LDE225** Advanced Basal Cell Carcinoma	AIN457 Ankylosing spondylitis	LEE011 Breast cancer	TKI258 Solid tumors	BGJ398 Solid tumors
Zykadia™*** ALK+ advanced NSCLC ³	AIN457 Psoriatic arthritis	LGX818 BRAF Mutant Melanoma	ACZ885 Sec. Prev. CV events ¹⁶	BGS649 OHH ¹⁹
Afinitor® HER2+ Breast cancer 1 st Line	AIN457 Rheumatoid arthritis	MEK162 NRAS Mutant Melanoma	CTL019 DLBCL ¹⁷	BYL719 Solid tumors
Afinitor® HER2+ Breast cancer 2 nd /3 rd Line	Gilenya® PPMS ⁷	MEK162 + LGX818 BRAF Mutant Melanoma		CAD106 Alzheimer's disease
Jakavi®**** Polycythemia vera	PKC412 ASM ⁸	RLX030 Acute Heart Failure		FCR001 Renal transplantation
Exjade® FCT ⁴ ***** Iron overload		Afinitor® TSC ¹⁰ Seizure		HSC835 Stem cell transplantation
		BKM120 mBC ER+ post AI and mTOR inhibitor		INC280 Solid tumors
		Gilenya® CIDP ¹¹		LIK066 Type II diabetes
		Ilaris® Hereditary Periodic Fevers		LJM716 Solid tumors
		Lucentis® CNV and ME ¹²		QAW039 Asthma
		MEK162 LGSOC ¹³		
		Tasigna® CML Treatment free remission		
		Tekturna® Heart failure ¹⁴		
		Zykadia™ ALK+advanced NSCLC ³ (first line, treatment naive)		
		Signifor® LAR ¹⁵ Cushing's Disease		

* LBH589 was filed in the US and EU in Q2 2014
 ** LDE225 was filed in EU in Q2 2014, US application submitted in Q3
 *** Zykadia™ (ceritinib) was approved in the US on April 29, 2014
 **** Jakavi® was filed in the EU in Q2 2014 and submitted in Japan in Q3
 ***** Exjade® FCT was submitted in the US in Q2 2014

New molecule
New indication
New formulation

¹ Familial chylomicronemia syndrome
² Reduced ejection fraction
³ Non-small cell lung cancer
⁴ Film-coated table
⁵ Acute myeloid leukemia
⁶ Neuroendocrine tumors
⁷ Primary progressive multiple sclerosis
⁸ Aggressive systemic mastocytosis
⁹ Sporadic inclusion body myositis
¹⁰ Tuberous sclerosis complex

¹¹ Chronic inflammatory demyelinating polyradiculoneuropathy
¹² Choroidal neovascularization (CNV) and macular edema (ME) secondary to conditions other than macular degeneration, diabetic macular edema, retinal vein occlusion and pathologic myopia
¹³ Low-grade serous ovarian cancer
¹⁴ Reduction of CV death/hospitalization in chronic heart failure patients

¹⁵ Long-acting release
¹⁶ Secondary prevention of cardiovascular events
¹⁷ Diffuse large B-cell lymphoma
¹⁸ Chronic obstructive pulmonary disease
¹⁹ Obese hypogonadotropic hypogonadism
²⁰ Preserved ejection fraction
²¹ Retinopathy of prematurity